Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Sarcoma × Immunoconjugates × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Rectal Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Stomach Neoplasms 1 Sarcoma 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Colonic Neoplasms 1

Interventions

Doxorubicin 33 pembrolizumab 16 Gemcitabine 15 eribulin 10 Irinotecan 10 olaratumab 9 Trabectedin 9 pazopanib 8 Docetaxel 8 Injections 7 Cyclophosphamide 7 Nivolumab 6 Fluorouracil 6 anlotinib 5 Temozolomide 5 Ipilimumab 5 Ifosfamide 5 tazemetostat 4 ridaforolimus 4 Drug Therapy 4 Cetuximab 4 Carboplatin 4 Bevacizumab 4 toripalimab 3 surufatinib 3 spartalizumab 3 ganitumab 3 entrectinib 3 conatumumab 3 belinostat 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06797999 2026-01-28

ADCElerate1

Adcendo ApS

Phase 1/2 Recruiting

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡